Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + tetracaine is a fixed-dose combination of two local anesthetics used topically to numb the skin before minor medical or cosmetic procedures, such as blood draws, IV insertions, skin biopsies, laser treatments, dermal filler injections, and tattoo removal[1][3][4][5]. Both components act by blocking sodium channels in neuronal membranes (sodium channel antagonists), thereby inhibiting nerve impulse conduction and producing localized loss of sensation without causing unconsciousness[1][6]. The combination is available as a prescription-only cream or patch. It was originally developed by ZARS and has been further developed or marketed by companies including Crescita Therapeutics, Galderma, and Nuvo Research[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + tetracaine.